Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].

Core Insights - Wu Yifang has joined Cloudbreak Capital as the Chairman of the Board of Cloudtop New Horizon after leaving Fosun Pharma, marking a new chapter in his career [1][2] Company Changes - Cloudtop New Horizon announced several board changes, including the appointment of Wu Yifang as Chairman, the transition of Fu Wei to a non-executive director, and the resignation of Feng Honggang as a non-executive director [1] - The adjustments aim to strengthen corporate governance, optimize strategic layout, and enhance overall company strength [1] Background of Wu Yifang - Wu Yifang has over 20 years of experience at Fosun Pharma, where he served as Chairman and CEO for nearly a decade, leading the company to achieve significant revenue growth [2][3] - Under his leadership, Fosun Pharma's revenue reached 41.07 billion yuan in 2024, with a steady increase from 30.31 billion yuan in 2020 [2] Strategic Focus - Wu Yifang's role at Cloudtop New Horizon will involve working closely with CEO Luo Yongqing to drive company development and provide strategic guidance on key initiatives, including strategic transactions and R&D innovation [1] - Cloudtop New Horizon is actively developing its mRNA business, which aligns with Wu Yifang's previous success in introducing BioNTech's mRNA technology to the Greater China region during his tenure at Fosun Pharma [4] Investment Management - Cloudtop New Horizon is a representative case incubated by Cloudbreak Capital, which manages assets worth $10.5 billion and focuses on the healthcare sector [4] - Cloudbreak Capital remains the largest shareholder of Cloudtop New Horizon, holding a 24.19% stake after a share placement [4] R&D Initiatives - Cloudtop New Horizon showcased its AI+mRNA technology platform during the "2025 Cloudtop New Horizon mRNA Innovation Technology Platform R&D Day," highlighting advancements in core pipelines for cancer and autoimmune diseases [5] - The company has initiated clinical trial applications for its therapeutic vaccines, EVM14 and EVM16, with EVM14's application officially accepted by the National Medical Products Administration [6]

Group 1 - Wu Yifang has been appointed as the Chairman of the Board of Directors at Genscript Biotech (云顶新耀) after becoming an Executive Operating Partner at Kangqiao Capital [1][3] - The board adjustments at Genscript Biotech aim to enhance corporate governance, optimize strategic layout, and improve overall strength [1][3] - Wu Yifang has over 30 years of experience in the pharmaceutical industry and previously served as Chairman and CEO of Fosun Pharma, leading its transformation into a global biopharmaceutical leader [3] Group 2 - Genscript Biotech is focusing on developing its mRNA business, with a fully integrated and localized AI+mRNA platform targeting oncology and autoimmune diseases [3][4] - The company is advancing its product pipeline, including the universal therapeutic vaccine EVM14 and personalized therapeutic vaccine EVM16, with the first patient dosing of EVM16 completed in March this year [3] - Genscript Biotech is implementing a "dual-driven" strategy of "licensing in + independent research and development," aiming for operational profitability by the second half of 2025 [4]

导语：2021至2025年，复星医药通过系统性资产剥离回笼资金超130亿元，但截至2025年上半年，其短期债务约226.46亿元，偿债缺口仍高达96.87亿 元。 近日， 复星医药公告，控股子公司复星医药产业 宣布 拟通过专项基金转让上海克隆 100% 股权及债权，交易对价不超过 12.56 亿元。 战略调整与资金缺口 标的资产为上海市徐汇区宜山路 1289 号工业用地及地上建筑，宗地面积 19,944 平方米，建筑面积 45,238.55 平方米。 标的 资产 紧邻漕河泾开发区，双地铁交汇， 周边地价较 2015 年已翻倍。漕河泾开发区是上海科创中心六大承载区之一，具备国家级经开区、 高新区、出口加工区三重身份，产业基础雄厚，汇聚 3600 余家高科技企业、 80 余家世界 500 强。 为填补资金 缺口，据 复星医药公告及权威财经媒体披露， 2021 至 2025 年，复星医药通过系统性资产剥离回笼资金超 130 亿元，核心目标聚 焦"非战略非核心资产退出"与"创新药 + 高值器械"双轮驱动转型。 据网易 2025 年 8 月地产分析，该区域工业用地改造潜力巨大，外资生命科学企业 可能可以 通过收购成熟园 ...

Core Viewpoint - The recent appointment of Wu Yifang as Executive Operating Partner at Kangqiao Capital marks a significant shift in the leadership landscape of Fosun Pharma, indicating a potential new direction for both companies in the biopharmaceutical sector [1][2][3]. Group 1: Leadership Changes - Wu Yifang has over 30 years of experience in the pharmaceutical industry and previously served as the CEO and Chairman of Fosun Pharma, where he played a crucial role in transforming the company into a global leader [2][3]. - His departure from Fosun Pharma, which includes a series of high-profile resignations, signifies the end of an era for the company, as he was a key figure in its recent successes [3][4]. - The management shake-up at Fosun Pharma has seen multiple executives leave, including the resignation of the Executive President and several senior vice presidents, indicating a comprehensive restructuring of the leadership team [5][6][7]. Group 2: Company Performance - During Wu Yifang's tenure as Chairman from 2020 to 2024, Fosun Pharma achieved revenues of 30.31 billion yuan, 39.01 billion yuan, 43.95 billion yuan, 41.40 billion yuan, and 41.07 billion yuan, showcasing significant growth [3][4]. - Despite the leadership changes, Fosun Pharma reported a revenue of 19.514 billion yuan in the first half of 2025, a year-on-year decrease of 4.63%, while net profit attributable to shareholders increased by 38.96% to 1.702 billion yuan, primarily due to asset sales [7][8]. - The company is focusing on increasing investment in innovative drugs to mitigate the impact of centralized procurement on its performance, with innovative drug revenue exceeding 4.3 billion yuan in the first half of 2025, a year-on-year increase of 14.26% [8].

Core Viewpoint - Kangqiao Capital appointed Wu Yifang as Executive Operating Partner, bringing extensive experience from Fosun International and Fosun Pharma [1] Group 1 - Wu Yifang previously served as the Executive Vice President of Fosun International [1] - Wu held the position of Chairman and CEO of Fosun Pharma for nearly ten years [1] - The appointment is expected to enhance Kangqiao Capital's operational capabilities [1]

证券代码：600196 股票简称：复星医药 编号：临2025-155 上海复星医药（集团）股份有限公司 关于非执行董事、高级管理人员 辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 2025年9月30日，上海复星医药（集团）股份有限公司（以下简称"本公司"）董事会分别收到吴以芳先 生、周旭东先生的书面辞职函，具体如下： 一、因个人工作变动，吴以芳先生向董事会申请辞去非执行董事职务。根据《上海复星医药（集团）股 份有限公司章程》（以下简称"《公司章程》"）规定，吴以芳先生的辞任于送达董事会时生效。吴以芳 先生已确认，其于任期内与董事会之间概无分歧。 吴以芳先生的辞任不会导致本公司董事会成员人数低于《中华人民共和国公司法》规定的法定最低人 数，不会对董事会的正常运作产生影响。本公司将依据《公司章程》的规定，尽快就补选董事事宜履行 相应程序。 董事会对吴以芳先生于本公司任职董事期间的工作表示感谢。 二、因个人发展原因，周旭东先生向董事会申请辞去高级副总裁职务。周旭东先生自2025年9月30日起 不再担任本公司高级副总裁职 ...

公开资料显示，2024年11月，复宏汉霖与沙特阿拉伯SVax公司达成战略合作。双方将在沙特阿拉伯分 别设立商业化和生产合资公司，并在MENAT地区就复宏汉霖的一系列产品，包括阿达木单抗汉达远 (HLX03)、贝伐珠单抗汉贝泰(HLX04)，进行合作开发，开展本地注册、生产及商业化。另外，此次合 作框架中的首批项目亦包括共同投资开发复宏汉霖自研的帕博利珠单抗生物类似药HLX17，共同推动 该产品的全球注册上市。 消息面上，复星医药中东办公室及合资公司Fosunhenlius Middle East United Company在沙特吉达正式揭 牌，标志着其在中东地区的本土化运营迈出关键一步。该合资公司由复星医药旗下复宏汉霖与沙特领先 药企SVax共同组建，将整合全球研发资源与本地化优势，为中东、北非及土耳其地区患者提供可负担 的高品质生物药。 复宏汉霖(02696)现涨超10%，截至发稿，涨9.33%，报77.95港元，成交额8233.55万港元。 ...

公开资料显示，2024年11月，复宏汉霖与沙特阿拉伯SVax公司达成战略合作。双方将在沙特阿拉伯分 别设立商业化和生产合资公司，并在MENAT地区就复宏汉霖的一系列产品，包括阿达木单抗汉达远 （HLX03）、贝伐珠单抗汉贝泰（HLX04），进行合作开发，开展本地注册、生产及商业化。另外， 此次合作框架中的首批项目亦包括共同投资开发复宏汉霖自研的帕博利珠单抗生物类似药HLX17，共 同推动该产品的全球注册上市。 消息面上，复星医药中东办公室及合资公司Fosunhenlius Middle East United Company在沙特吉达正式揭 牌，标志着其在中东地区的本土化运营迈出关键一步。该合资公司由复星医药旗下复宏汉霖与沙特领先 药企SVax共同组建，将整合全球研发资源与本地化优势，为中东、北非及土耳其地区患者提供可负担 的高品质生物药。 智通财经APP获悉，复宏汉霖(02696)现涨超10%，截至发稿，涨9.33%，报77.95港元，成交额8233.55万 港元。 ...

经观健康 经济观察网 9 月 30 日，上海复星医药（集团）股份有限公司发布公告，表示董事会已分别收到吴以芳、周旭东的书面辞职函。据复星医药公告，因个人工 作变动，吴以芳向复星医药董事会申请辞去非执行董事职务，辞任于送达董事会时生效。 2016 年以来，吴以芳曾任职董事长、执行董事、首席执行官、总裁职务，直至今年 4 月底卸任所有职务，仅保留非执行董事一职。 吴以芳于1987 年 6 月至 1997 年 4 月期间历任徐州生物化学制药厂技术员、主任、生产科长、财务主任、厂长助理、副厂长等职，这家药企后改名万邦生 化，是万邦医药的前身。2004 年 4 月，万邦生化改制，加入复星医药集团，成为复星医药控股子公司。 2007 年 3 月，吴以芳被任命为江苏万邦总裁，2011 年 4 月至 2020 年 10 月期间任江苏万邦董事长兼首席执行官，同时在 2014 年 7 月至 2016 年 1 月期间， 任复星医药高级副总裁。 2016 年 6 月 7 日，吴以芳就任复星医药总裁兼首席执行官职务，并于同年 8 月起任复星医药执行董事。 近一年来，复星医药已发生过多次高管变动。 去年 9 月 13 日，复星医药执行总 ...